ExpreS2ion’s core platform patent allowed in India
Hørsholm, Denmark, December 28, 2017 – Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in India and will be granted with expiry June 12, 2029.
“Obtaining a strong patent protection in India, one of the world’s largest markets for vaccine technology, is an important step towards our goal to have the ExpreS2 platform protected in all major markets and consolidate our position as a global player. We are now close to reaching this goal," says Steen Klysner, CEO of ExpreS2ion.
The patent application “Improved Protein Expression System” has been filed in 15 different countries covering the company’s major markets. The patent has been issued in the United States, South Korea, Japan, Australia and China, and validated in several EU countries following approval by the European Patent Office.
Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on December 28, 2017.
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion’s unique proprietary platform technology, ExpreS2, is designed to enable accelerated, cost effective development and robust production of complex proteins for new vaccines and diagnostics. Since founded in 2010, more than 250 proteins involved in e.g. malaria and Zika were produced in collaborations with research institutions and companies with a superior efficiency and success rate. ExpreS2ion also develops competitive virus-like-particle based vaccines through its joint venture AdaptVac, which was founded in 2017.